Abstract
The success of allogeneic hematopoietic cell transplantation (HCT) for B-cell malignancies is evidence that these tumors can be eliminated by T lymphocytes. This has encouraged the development of specific adoptive T-cell therapy, both for augmenting the anti-tumor effect of HCT and for patients not undergoing HCT. T cells that are capable of recognizing antigens expressed on malignant B cells may be recruited from the endogenous repertoire or engineered to express tumor-targeting receptors. Critical insights into the qualities of T cells that enable their persistence and function in vivo have been derived, and obstacles to effective T-cell-mediated tumor eradication are being elucidated. These advances provide the tools to translate adoptive T-cell transfer into reliable clinical therapies.
Original language | English (US) |
---|---|
Pages (from-to) | 517-532 |
Number of pages | 16 |
Journal | Expert Review of Hematology |
Volume | 2 |
Issue number | 5 |
DOIs | |
State | Published - 2009 |
Keywords
- Adoptive T-cell therapy
- Allogeneic hematopoietic cell transplantation
- Central memory T cell
- Chimeric antigen receptor
- Graft-versus-host disease
- Graft-versus-tumor effect
- Immunoglobulin idiotype
- Minor histocompatibility antigen
- T-cell receptor
ASJC Scopus subject areas
- Hematology